Sarcomatrix Therapeutics Opens Accredited Investor Round for Once-Daily Pill to Address Duchenne Across Genetic Mutation
Sarcomatrix opens its accredited investor round to advance S-969, a once-daily, mutation-agnostic oral therapy for Duchenne toward human trials. RENO, NV, UNITED STATES, July 24, 2026 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE Sarcomatrix …